

10/1/01
diameter within the range 0.05 um to 11 um and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 um, wherein the second particulate material has a Mohs hardness value of less than 6.5.

Please amend claim 2 as follows:

2. (Amended) Composition according to claim 1 wherein the second particulate material has a median volume diameter within the range 20 to 125 um.

Please amend claim 3 as follows:

3. (Amended) Composition according to claim 1 wherein the weight ratio of first particulate material to second particulate material in the composition lies in the range 1:0.1 to 1:500.

Please amend claim 4 as follows:

4. (Amended) Composition according to claim 3 wherein the weight ratio of first particulate material to second particulate material in the composition lies in the range 1:10 to 1:100.

Please amend claim 5 as follows:

5. (Amended) Composition according to claim 1 wherein the first particulate material has a median aerodynamic diameter within the range 1 to 10 um.

Please amend claim 6 as follows:

6. (Amended) Composition according to claim 1 wherein the second particulate material has a Mohs hardness value of less than 5.

Please amend claim 7 as follows:

7. (Amended) Composition according to claim 1 wherein the second particulate material has a Carr Index value:

for particles more than 100 um in size of less than 14%;

for particles 40 to 100 um in size of less than 28%;

for particles 20 to 40 um in size of less than 35%; and

for particles less than 20 um in size of less than 65%.

[Please amend claim 8 as follows:]

8. (Amended) Composition according to claim 1 wherein the solubility of the first particulate material in the propellant is less than 49.9 wt% with respect to the total weight of the substance present in the composition comprising the first particulate material.

[Please amend claim 9 as follows:]

9. (Amended) Composition according to claim 1 wherein the solubility of the second particulate material in the propellant is less than 49.9 wt% with respect to the total weight of the substance present in the composition comprising the second particulate material.

[Please amend claim 10 as follows:]

10. (Amended) Composition according to claim 1 wherein the composition comprises at least 80 wt% and up to 99.999 wt% propellant.

[Please amend claim 11 as follows:]

11. (Amended) Composition according to claim 10 wherein the composition comprises at least 0.001 wt% and up to 20 wt% of the total of the first and second particulate material present.

[Please amend claim 12 as follows:]

12. (Amended) Composition according to claim 1 further comprising a surfactant, flavouring material, buffer, preservative or any mixture thereof.

[Please amend claim 13 as follows:]

13. (Amended) Composition according to claim 1 wherein the propellant is selected from the group consisting of chlorofluorocarbons, hydrofluorocarbons, and mixtures thereof.

A1 [Please amend claim 14 as follows:]

14. (Amended) Composition according to claim 13 wherein the propellant is selected from the group consisting of hydrofluorocarbons and mixtures thereof.

[Please amend claim 16 as follows:]

16. (Amended) Composition according to claim 1 wherein the second particulate material is selected from carbohydrates including sugars, mono-, di-, tri-, oligo-, and poly-saccharides, and any physiologically acceptable derivatives, salts, forms, and solvates thereof, and any mixtures thereof.

A2 [Please amend claim 17 as follows:] B

17. (Amended) Composition according to claim 1 wherein the second particulate material is selected from amino acids, di-, tri-, oligo-, and poly-peptides, proteins and any physiologically acceptable derivatives, salts, forms and solvates thereof and mixtures thereof.

[Please amend claim 18 as follows:]

18. (Amended) Composition according to claim 1 wherein the first particulate material is a medicament.

[Please amend claim 19 as follows:]

19. (Amended) Composition according to claim 18 wherein the medicament is selected from the group consisting of salbutamol, salbutamol sulphate, terbutaline, terbutaline sulphate, ipratropium bromide or any physiologically acceptable salts or solvates thereof; beclomethasone dipropionate, budesonide, triamcinolone acetonide or any physiologically acceptable solvates thereof; corticosteroid, bronchodilator; peptides, proteins, nucleic acids or derivatives thereof; insulin, calcitonin, growth hormone, luteinizing hormone releasing hormone, leuprolide, and oxytocin or any physiologically acceptable salts or solvates thereof, and any mixture thereof.

Please amend claim 20 as follows:

20. (Amended) Composition according to claim 18 wherein the medicament is salmeterol xinafoate, or any mixture thereof with any one of the group consisting of salbutamol, salbutamol sulphate, terbutaline, terbutaline sulphate, ipratropium bromide or any physiologically acceptable salts or solvates thereof; beclomethasone dipropionate, budesonide, triamcinolone acetonide or any physiologically acceptable solvates thereof; corticosteroid, bronchodilator; peptides, proteins, nucleic acids or derivatives thereof; insulin, calcitonin, growth hormone, lutensing hormone releasing hormone, leuprolide, and oxytocin or any physiologically acceptable salts or solvates thereof, and any mixture thereof.

Please amend claim 21 as follows:

21. (Amended) Composition according to claim 19 wherein the medicament is salbutamol sulphate.

Please amend claim 22 as follows:

22. (Amended) Composition according to claim 18 wherein the medicament is fluticasone propionate, or any mixture thereof with any one of the group consisting of salbutamol, salbutamol sulphate, terbutaline, terbutaline sulphate, ipratropium bromide or any physiologically acceptable salts or solvates thereof; beclomethasone dipropionate, budesonide, triamcinolone acetonide or any physiologically acceptable solvates thereof; corticosteroid, bronchodilator; peptides, proteins, nucleic acids or derivatives thereof; insulin, calcitonin, growth hormone, lutensing hormone releasing hormone, leuprolide, and oxytocin or any physiologically acceptable salts or solvates thereof, and any mixture thereof.

Please amend claim 23 as follows:

23. (Amended) Composition according to claim 18 wherein the medicament is beclomethasone dipropionate or a physiologically acceptable solvate thereof, or any mixture thereof with any one of the group consisting of salbutamol, salbutamol sulphate, terbutaline, terbutaline sulphate, ipratropium bromide or any physiologically acceptable salts or solvates thereof; beclomethasone dipropionate, budesonide, triamcinolone acetonide or any physiologically acceptable solvates thereof; corticosteroid, bronchodilator; peptides, proteins, nucleic acids or derivatives thereof; insulin, calcitonin, growth hormone, lutensing hormone releasing hormone, leuprolide, and oxytocin or any physiologically acceptable salts or solvates thereof, and any mixture thereof.

A2/B37
[Please amend claim 24 as follows:]

24. (Amended) Pharmaceutical composition comprising a propellant and contained therein a particulate medicament comprising particles having a median aerodynamic diameter within the range 0.05 to 11 μ m and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 μ m, wherein the second particulate material has a Mohs hardness value of less than 6.5.

Please amend claim 26 as follows:

26. (Amended) A container according to claim 25 wherein the valve outlet is a metered dose valve.

A3
[Please amend claim 27 as follows:]

27. (Amended) An inhalation device incorporating a container according to claim 25.

Please amend claim 32 as follows:

32. (Amended) The method according to claim 31 wherein the container includes an outlet valve.

A4/B37
[Please amend claim 33 as follows:]

33. (Amended) A mixture of first particulate material having a median aerodynamic diameter within the range 0.05 to 11 μ m and a second particulate material having a median volume diameter within the range of 15 to 200 μ m, wherein the second particulate material has a Mohs hardness value of less than 6.5.

Please add new claim 36 as follows:

36. (New) Composition according to claim 1 wherein the second particulate material has a Mohs hardness value of less than 4. *B*

A5
[Please add new claim 37 as follows:]